Defunct Company
Total Trials
12
As Lead Sponsor
9
As Collaborator
3
Total Enrollment
13,473
NCT03451240
A Mixed Methods Evaluation of HPI Resilience Intervention Study
Phase: N/A
Role: Collaborator
Start: Sep 16, 2017
Completion: Dec 31, 2017
NCT03425409
Aviation Portable Oxygen Delivery System
Start: Sep 1, 2018
Completion: Oct 1, 2018
NCT05227261
Early Detection of Five Common Cancers Using the ctDNA Analysing Test
Role: Lead Sponsor
Start: Apr 10, 2022
Completion: Apr 10, 2024
NCT06087120
Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment
Start: Sep 16, 2023
Completion: Dec 31, 2025
NCT06167460
Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC.
Start: Dec 4, 2023
Completion: Dec 1, 2025
NCT06227728
Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.
Start: Mar 22, 2024
Completion: Dec 31, 2026
NCT06385366
Developing & Evaluating Models for Early Predicting Obstetrical Diseases in Pregnant Women by Non-invasive Prenatal Test
Start: May 10, 2024
Completion: Nov 6, 2025
NCT06589388
ctDNA Monitoring to Predict the Efficacy of TNT for Rectal Cancer
Start: May 21, 2024
Completion: Dec 31, 2027
NCT06391749
Clinical Validation of an MCED Test in Symptomatic Populations (K-ACCELERATE)
Start: Jul 30, 2024
Completion: Jul 31, 2026
NCT06863038
Predictive Value of PREMM5, MMRpredict, and Universal Tumor Screening for Lynch Syndrome in Vietnam
Start: Mar 17, 2025
Completion: Nov 30, 2027
NCT06929910
Assessing Systemic Treatment and ctDNA Monitoring Efficacy in Metastatic Cancer Patients Using K4Care Testing.
Start: Apr 9, 2025
Completion: Jun 30, 2027
NCT07126626
Validation of the SPOT-MAS Lung Test Using Circulating Tumor DNA for the Detection of Lung Cancer
Start: Aug 18, 2025
Completion: Jul 31, 2027